DOI: 10.1007/s00259-018-4184-zPages: 1-3

I-131 as adjuvant treatment for differentiated thyroid carcinoma may cause an increase in the incidence of secondary haematological malignancies: an “inconvenient” truth?

1. University Hospital Marburg, Department of Nuclear Medicine

2. Oncology Institute of Southern Switzerland, Department of Nuclear Medicine and Thyroid Centre

3. Papageorgiou Hospital, Academic Department of Nuclear Medicine

4. Erasus MC, Department of Nuclear Medicine

5. St Vincent’s Hospital, Department of Nuclear Medicine and Endocrinology, PET-CT Center LINZ

6. University Hospital Würzburg, Department of Nuclear Medicine

7. Oncology Institute of Vojvodina, Department of Nuclear Medicine

Correspondence to:
Frederik A. Verburg
Tel: +49-6421-5862815
Email: verburg@med.uni-marburg.de

Close

Abstract

This article is freely available, click here to access the full text/PDF

  • Accepted: Sep 27, 2018
  • Online: Oct 8, 2018

Article Tools

eanm
EJNMMI Ad